Incyte Corp INCY Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$119.65 up $1.64, 1.39% at close Nov 6
Last close · Previous close $118.01
- Market cap
- At the Nov 6 close
- P/E ratio
- 63.64On last 12 months’ EPS
- Diluted EPS
- $1.88Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$119.65up $1.64, 1.39%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$118.01Nov 5
- Volume1.49MNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume1.88MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $89.25 to $132.60; now $119.65
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
INCY beat the S&P 500 in 6 of 7 periods.
| Period | INCY and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | INCY: up 6.1% S&P 500: down 5.6% | INCY beat the S&P 500 by 11.7 percentage points Beat |
| 3M | INCY: up 1.1% S&P 500: down 4.1% | INCY beat the S&P 500 by 5.2 percentage points Beat |
| YTD | INCY: up 21.1% S&P 500: up 8.7% | INCY beat the S&P 500 by 12.4 percentage points Beat |
| 1Y | INCY: up 13.7% S&P 500: up 10.9% | INCY beat the S&P 500 by 2.8 percentage points Beat |
| Long term | ||
| 3Y | INCY: up 119.3% S&P 500: up 75.0% +29.9% vs +20.5% a year | INCY beat the S&P 500 by 44.3 percentage points Beat |
| 5Y | INCY: up 76.3% S&P 500: up 67.8% +12.0% vs +10.9% a year | INCY beat the S&P 500 by 8.5 percentage points Beat |
| 10Y | INCY: up 36.6% S&P 500: up 313.1% +3.2% vs +15.2% a year | INCY trailed the S&P 500 by 276.5 percentage points Trailed |
$10,000 invested in INCY 10 years ago (Nov 4, 2016) would be worth about $13,663 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
INCY beat the S&P 500 in 6 of 7 periods.
| Period | INCY and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | INCY: up 6.1% S&P 500: down 5.6% | INCY beat the S&P 500 by 11.7 percentage points Beat |
| 3M | INCY: up 1.1% S&P 500: down 4.3% | INCY beat the S&P 500 by 5.4 percentage points Beat |
| YTD | INCY: up 21.1% S&P 500: up 7.8% | INCY beat the S&P 500 by 13.3 percentage points Beat |
| 1Y | INCY: up 13.7% S&P 500: up 9.7% | INCY beat the S&P 500 by 4.0 percentage points Beat |
| Long term | ||
| 3Y | INCY: up 119.3% S&P 500: up 68.8% +29.9% vs +19.1% a year | INCY beat the S&P 500 by 50.5 percentage points Beat |
| 5Y | INCY: up 76.3% S&P 500: up 56.9% +12.0% vs +9.4% a year | INCY beat the S&P 500 by 19.4 percentage points Beat |
| 10Y | INCY: up 36.6% S&P 500: up 252.6% +3.2% vs +13.4% a year | INCY trailed the S&P 500 by 216.0 percentage points Trailed |
$10,000 invested in INCY 10 years ago (Nov 4, 2016) would be worth about $13,663 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$152.66
Closing high on . Now 21.6% below that record.
Split-adjusted daily closes since Nov 4, 1993.
Stock splits
2
Latest: 2-for-1 on . One share bought before the first split is 4 shares today.
Both splits
- 2-for-1
- 2-for-1
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q3 FY26, the quarter ended Sep 30, 2026. “Last 12 months” means the four quarters from Oct 1, 2025 to Sep 30, 2026, and balance-sheet figures are as of Sep 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $6.01Bup 24.9%
- Net income
- $403.41Mdown 66.1%
- Diluted EPS
- $1.88down 68.1%
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY24 (Dec 31, 2024) | $1.18B | $201.21M | $0.95 |
| Q1 FY25 (Mar 31, 2025) | $1.05B | $158.20M | $0.80 |
| Q2 FY25 (Jun 30, 2025) | $1.22B | $405.00M | $2.04 |
| Q3 FY25 (Sep 30, 2025) | $1.37B | $424.17M | $2.11 |
| Q4 FY25 (Dec 31, 2025) | $1.51B | $299.28M | $1.46 |
| Q1 FY26 (Mar 31, 2026) | $1.27B | $303.33M | $1.47 |
| Q2 FY26 (Jun 30, 2026) | $1.67B | $585.61M | $2.81 |
| Q3 FY26 (Sep 30, 2026) | $1.56B | −$784.80M | −$3.86 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $2.99B | $948.58M | $4.27 |
| FY22 (Dec 31, 2022) | $3.39B | $340.66M | $1.52 |
| FY23 (Dec 31, 2023) | $3.70B | $597.60M | $2.65 |
| FY24 (Dec 31, 2024) | $4.24B | $32.62M | $0.15 |
| FY25 (Dec 31, 2025) | $5.14B | $1.29B | $6.41 |
Margins
- Gross 92.7%
- Operating 10.4%
- Net 6.7%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- $684.87MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$744.99MLast 12 months
- Capital spending$60.12MLast 12 months
- 11.4%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $455.59MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
0% of free cash flow
Balance sheet
- $3.95BAs of Sep 30, 2026
Cash plus short- and long-term marketable securities on the Sep 30, 2026 balance sheet.
- Total debt$31.76MAs of Sep 30, 2026
- Net cash$3.92BAs of Sep 30, 2026
- 3.84As of Sep 30, 2026
Current assets divided by current liabilities on the Sep 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.01As of Sep 30, 2026
Total debt divided by shareholders’ equity on the Sep 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 5 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✓Net income was positive: passed
- ✓Operating cash flow was positive: passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✓Long-term debt fell relative to assets: passed
- ✓Current ratio improved: passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- 7.1%Last 12 months
Over the last 12 months, Incyte’s net income was 7.1% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - 5.5%Last 12 months
Over the last 12 months, Incyte’s net income was 5.5% of its total assets (averaged over the last four quarter-ends): what the business earned on everything it owns.
ROA = Net income (last 12 months) ÷ Average total assets
About Incyte Corp
A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Delaware, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
INCY news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
INCY stock FAQ
What is INCY stock’s price today?
Incyte (INCY) traded at $119.65 at the close on , up $1.64 (1.39%) from the previous close of $118.01. Over the past 52 weeks it has traded between $89.25 and $132.60.
If you invested $1,000 in INCY 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in INCY on would be worth about $1,366 at the close on , a total return of +36.6%. The same $1,000 would be worth $1,763 if invested five years ago, $1,137 if invested one year ago, $24,670 if invested 20 years ago, and $12,194 if invested 30 years ago. Past performance doesn’t predict future returns.
What is INCY’s P/E ratio?
INCY trades at 63.6 times its diluted earnings over the four quarters to ($1.88 per share), at the close. (How the P/E ratio works.)
How much revenue does Incyte make?
Incyte reported $6.0 billion of revenue over the four quarters to , up 24.9% from the twelve months before. In its latest quarter (Q3 FY26, ended ) revenue was $1.6 billion, up 14.0% from a year earlier.
Is Incyte profitable?
Yes. Incyte earned $403.4 million of net income over the four quarters to , a net margin of 6.7%, and its operating margin was 10.4% (what margins tell you).
What are INCY’s earnings per share?
INCY’s diluted earnings per share were $1.88 over the four quarters to , compared with $5.90 in the twelve months before. The latest quarter (Q3 FY26) brought −$3.86 per share, against $2.11 a year earlier (how EPS works).
Does INCY pay a dividend?
Incyte hasn’t paid a dividend in the last twelve months.
What is INCY’s 52-week high and low?
Over the past 52 weeks INCY has traded as low as $89.25 and as high as $132.60. At $119.65 at the close on , it is 9.8% below that high and 34.1% above the low.
What is INCY’s all-time high?
INCY’s highest closing price was $152.66 on , adjusted for stock splits. At $119.65 at the close on , it is 21.6% below that record.
Has INCY stock ever split?
Yes, twice: 2-for-1 on ; 2-for-1 on . One share bought before the first split would be 4 shares today.
How has INCY stock performed?
Including dividends and measured to the close on , INCY has returned +21.1% so far this year and +13.7% over the past year, and +76.3% over five years (+12.0% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Incyte in?
Incyte is in the Healthcare sector and the Biotechnology industry, and is headquartered in Delaware, USA.
What exchange does INCY trade on?
Incyte trades on the Nasdaq under the ticker symbol INCY. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.